Netflix, DocuSign And A Health Care Stock On CNBC’s ‘Final Trades’

On CNBC’s “Halftime Report Final Trades,” Stephen Weiss, chief investment officer and managing partner of Short Hills Capital Partners, picked Netflix, Inc. (NASDAQ:NFLX).

On Oct. 9, Morgan Stanley analyst Sean Diffley maintained an Overweight rating on Netflix and lowered the price target from $83 to $80.

Jim Lebenthal, partner and chief market strategist at Cerity Partners, recommended AbbVie Inc. (NYSE:ABBV), saying momentum here is strong.

On Oct. 7, AbbVie disclosed that the Food and Drug Administration granted two Breakthrough Therapy Designations (BTDs) to telisotuzumab adizutecan.

Don’t forget to check out our premarket coverage here

Jenny Van Leeuwen Harrington, chief executive officer of Gilman Hill Asset Management, LLC, said DocuSign, Inc. (NASDAQ:DOCU) has nearly 10% free cash flow yield.

DocuSign posted better-than-expected financial results for the second quarter of fiscal 2027 on Sept. 3. Docusign posted second-quarter revenue of $875.75 million, beating the consensus estimate of $857.43 million, according to Benzinga Pro. The agreement management company reported adjusted earnings of $1.16 per share, beating estimates of $1.09 per share.

Price Action

• Netflix shares gained 0.4% to close at $70.61 on Monday.
• AbbVie gained 1.7% to settle at $281.12 on Monday.
• DocuSign shares slipped 0.2% to close at $70.97.

Photo via Shutterstock